Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Janux Therapeutics Inc

JANX
Current price
9.04 USD +0.26 USD (+2.96%)
Last closed 8.73 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 426 134 304 USD
Yield for 12 month -33.68 %
Week
Month
Year
JANX
21.11.2021 - 28.11.2021

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California. Address: 11099 North Torrey Pines Road, La Jolla, CA, United States, 92037

Analytics

WallStreet Target Price

26.25 USD

P/E ratio

Dividend Yield

Current Year

+8 612 000 USD

Last Year

+3 637 000 USD

Current Quarter

+2 517 000 USD

Last Quarter

+1 057 000 USD

Current Year

+8 612 000 USD

Last Year

+3 637 000 USD

Current Quarter

+2 517 000 USD

Last Quarter

+1 057 000 USD

Key Figures JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -73 281 000 USD
Operating Margin TTM -628.25 %
PE Ratio
Return On Assets TTM -12.31 %
PEG Ratio
Return On Equity TTM -18.4 %
Wall Street Target Price 26.25 USD
Revenue TTM 8 467 000 USD
Book Value 7.56 USD
Revenue Per Share TTM 0.2 USD
Dividend Share
Quarterly Revenue Growth YOY 38.8 %
Dividend Yield
Gross Profit TTM -44 829 000 USD
Earnings Share -1.47 USD
Diluted Eps TTM -1.47 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics JANX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation JANX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 33.5613
Price Sales TTM 71.6674
Enterprise Value EBITDA -4.0253
Price Book MRQ 1.6966

Financials JANX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators JANX

For 52 weeks

5.65 USD 23.64 USD
50 Day MA 8.29 USD
Shares Short Prior Month 2 713 156
200 Day MA 11.98 USD
Short Ratio 24.47
Shares Short 2 605 935
Short Percent 13.95 %